Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement (Details 2)

v3.6.0.2
Fair Value Measurement (Details 2) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Assets:      
Fair value of level 3 financial instruments as of December 31, 2015 $ 4,782    
Fair market value of stock received as partial repayment of note receivable (215)    
Cash payment received as partial repayment of note receivable (300)    
Viking note receivable fair market value adjustment (1,060)    
Fair value of level 3 financial instrument assets as of December 31, 2016 3,207 $ 4,782  
Liabilities      
Fair value of level 3 financial instruments as of December 31, 2015 9,490    
Other [1] 4,987    
Fair value of level 3 financial instruments as of December 31, 2016 1,604 9,490  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Payments to CVR holders and other contingency payments (8,777) (6,740) $ (3,493)
Fair value adjustments to contingent liabilities 3,400 5,000  
Viking Therapeutics, Inc.      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Equity Method Investment, Quoted Market Value 7,500    
2019 Convertible Senior Notes | Senior Notes      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair value of convertible debt 331,700    
CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Payments to CVR holders and other contingency payments (6,158) (5,848)  
Fair value adjustments to contingent liabilities $ 3,259 $ 3,800  
[1] Balance represents Cydex CVR obligation, which was determined based on actual amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016.